.
-as of [25 OCTOBER 2025]-
.
“si MET ih cone”
.
.
-[DIMETHICONE] + [SILICON DI-OXIDE]-
.
also known as simethicone (USAN),
Simeticone (INN) is an anti-foaming agent used to reduce bloating, discomfort or pain caused by excessive gas.
Simethicone tablets
Simeticone is used to relieve the symptoms of excessive gas in the gastrointestinal tract, namely bloating, burping, and flatulence.[2][3] While there is a lack of conclusive evidence that simeticone is effective for this use,[4][5][failed verification] studies have shown that it can relieve symptoms of functional dyspepsia[6] and functional bloating.[7]
It has not been fully established that simeticone is useful to treat colic in babies,[8] and it is not recommended for this purpose.[5] A study in the United Kingdom reported that according to parental perception simeticone helped infant colic in some cases.[9]
Simeticone can also be used for suspected postoperative abdominal discomfort in infants.[10]
Simeticone does not have any serious side effects.[11] Two uncommon side effects (occurring in 1 in 100 to 1 in 1,000 patients) are constipation and nausea.[12]
Simeticone is a non-systemic surfactant which decreases the surface tension of gas bubbles in the GI tract.[11] This allows gas bubbles to leave the GI tract as flatulence or belching.[11] Simeticone does not reduce or prevent the formation of gas.[13] Its effectiveness has been shown in several in vitro studies.[14][15]
Simeticone is a mixture of dimethicone and silicon dioxide.[16]
The INN name is “simeticone”, which was added to the INN recommended list in 1999.[17]
Simeticone is marketed under many brand names and in many combination drugs; it is also marketed as a veterinary drug.[18]
Brands
^ “Simethicone names”. Drugs.com. Retrieved 27 August 2017.
^ “Simethicone tablet”. NIH DailyMed. April 2016. Retrieved 27 August 2017.
^ “Simeticone”. NHS. 10 October 2019. Retrieved 30 January 2020.
^ Modi R, Clearfield HR, Levitt M (July 2013). “Belching, Bloating and Flatulence”. American College of Gastroenterology.
^ Jump up to: a b “Simethicone”. drugs.com. Efficacy not established for the symptomatic relief of immediate postprandial upper abdominal distress
^ Holtmann G, Gschossmann J, Mayr P, Talley NJ (September 2002). “A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia”. Alimentary Pharmacology & Therapeutics. 16 (9). Wiley: 1641–8. doi:10.1046/j.1365-2036.2002.01322.x. PMID 12197843. S2CID 23286985.
^ Burta O, Iacobescu C, Mateescu RB, Nicolaie T, Tiuca N, Pop CS (25 September 2018). “Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, randomised, double-blind, parallel group, clinical study”. Translational Gastroenterology and Hepatology. 3 (72). AME Publications: 72. doi:10.21037/tgh.2018.09.11. PMC 6256934. PMID 30511026.
^ Biagioli E, Tarasco V, Lingua C, Moja L, Savino F (September 2016). “Pain-relieving agents for infantile colic”. The Cochrane Database of Systematic Reviews. 2016 (9) CD009999. doi:10.1002/14651858.CD009999.pub2. PMC 6457752. PMID 27631535.
^ Goldman M, Beaumont T (March 2017). “A real world evaluation of a treatment for infant colic based on the experience and perceptions of 4004 parents”. British Journal of Nursing. 26 (5 Suppl 1): S3 – S10. doi:10.12968/bjon.2017.26.Sup5.S3. PMID 28350192. S2CID 32885530.
^ Voepel-Lewis TD, Malviya S, Burke C, D’Agostino R, Hadden SM, Siewert M, Tait AR (March 1998). “Evaluation of simethicone for the treatment of postoperative abdominal discomfort in infants”. Journal of Clinical Anesthesia. 10 (2): 91–94. doi:10.1016/S0952-8180(97)00249-3. PMID 9524891.
^ Jump up to: a b c Ingold CJ, Akhondi H (January 2021). “Simethicone”. StatPearls [Internet]. PMID 32310457.
^ “Simethicone Side Effects in Detail”. Drugs.com. Retrieved 27 August 2017.
^ “Treatment of Gas”. International Foundation for Functional Gastrointestinal Disorders. 4 September 2015.
^ Brecević L, Bosan-Kilibarda I, Strajnar F (May 1994). “Mechanism of antifoaming action of simethicone”. Journal of Applied Toxicology. 14 (3). Wiley: 207–11. doi:10.1002/jat.2550140311. PMID 8083482. S2CID 7453218. Retrieved 30 January 2020.
^ Dittrich M, Miederer SE, Havertz B, Krastev R (12 May 2010). “Schaumzerstörung und Schaumverhinderung: Der Wirkmechanismus von Simeticon in vitro” Defoaming and antifoaming action of simethicone in vitro. Journal für Gastroenterologische und Hepatologische Erkrankungen. (in German). 8 (3). Krause & Pachernegg: 19–25.
^ O’Neil MJ, ed. (2006). “Dimethicone”. The Merck Index (14th ed.). Whitehouse Station, NJ: Merck. p. 545.
^ “Recommended INN List 42” (PDF). WHO Drug Information. 13 (3): 202. 1999.
^ Jump up to: a b c “Simeticone international brands”. Drugs.com. Retrieved 27 August 2017
.
en.wikipedia.org /wiki/Simeticone
Simeticone
Contributors to Wikimedia projects6-7 minutes 10/24/2004
DOI: Parsing…
From Wikipedia, the free encyclopedia
(Redirected from Simethicone)
This article is missing information about the history of simeticone. Please expand the article to include this information. Further details may exist on the talk page. (September 2021)
Simeticone
Clinical data
Trade names Infacol, Wind-eze, WindSetlers, others
Other names Simethicone[1] (USAN US)
AHFS/Drugs.com Monograph
Pregnancy
category
C
Routes of
administration Oral
ATC code
A03AX13 (WHO)
Legal status
Legal status
US: OTC
Pharmacokinetic data
Bioavailability None
Protein binding 0%
Metabolism Not metabolized
Elimination half-life N/A
Excretion Feces
Identifiers
IUPAC name
CAS Number
8050-81-5 check
PubChem CID
6433516
DrugBank
DB09512 check
ChemSpider
None
ChEMBL
ChEMBL1200838 ☒
CompTox Dashboard (EPA)
DTXSID00904918 Edit this at Wikidata
ECHA InfoCard 100.107.016 Edit this at Wikidata
Chemical and physical data
Formula (C2H6OSi)n · (SiO2)m
Molar mass Variable
☒check (what is this?) (verify)
.
.
*👨🔬🕵️♀️🙇♀️*SKETCHES*🙇♂️👩🔬🕵️♂️*
.
.
.
👈👈👈☜*-OUR “MEDICINE CABINET”-* ☞ 👉👉👉
.
.
💕💝💖💓🖤💙🖤💙🖤💙🖤❤️💚💛🧡❣️💞💔💘❣️🧡💛💚❤️🖤💜🖤💙🖤💙🖤💗💖💝💘
.
.
*🌈✨ *TABLE OF CONTENTS* ✨🌷*
.
.
🔥🔥🔥🔥🔥🔥*we won the war* 🔥🔥🔥🔥🔥🔥